🇪🇺 EXVIERA in European Union

EMA authorised EXVIERA on 14 January 2015

Marketing authorisation

EMA — authorised 14 January 2015

  • Application: EMEA/H/C/003837
  • Marketing authorisation holder: AbbVie Ltd
  • Local brand name: Exviera
  • Indication: Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.
  • Pathway: accelerated assessment
  • Status: withdrawn

Read official source →

Other Virology / Hepatology approved in European Union

Frequently asked questions

Is EXVIERA approved in European Union?

Yes. EMA authorised it on 14 January 2015.

Who is the marketing authorisation holder for EXVIERA in European Union?

AbbVie Ltd holds the EU marketing authorisation.